購物車 
-
N4-羥基胞苷
NMR and HPLC COA下載 MSDS下載 - Names：
N4-Hydroxycytidine
- CAS號：
3258-02-4
MDL Number： - MF(分子式)： C3D11PV2O4 MW(分子量)： 259.0804352
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數(shù)量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| HCQ000013-1kg | 1kg | 98.36% | ￥ 0.00 | ￥ 0.00 | Get quote | ￥ 0.00 | ||
| HCQ000013-100mg | 100mg | 98.36% | ￥ 18000.00 | ￥ 18000.00 | Instock | ￥ 0.00 | ||
| HCQ000013-50mg | 50mg | 98.36% | ￥ 13200.00 | ￥ 13200.00 | Instock | ￥ 0.00 | ||
| HCQ000013-25mg | 25mg | 98.36% | ￥ 7920.00 | ￥ 7920.00 | Instock | ￥ 0.00 | ||
| HCQ000013-10mg | 10mg | 98.36% | ￥ 4400.00 | ￥ 4400.00 | Instock | ￥ 0.00 | ||
| HCQ000013-5mg | 5mg | 98.36% | ￥ 2800.00 | ￥ 2800.00 | Instock | ￥ 0.00 | ||
| HCQ000013-1mg | 1mg | 98.36% | ￥ 960.00 | ￥ 960.00 | Instock | ￥ 0.00 |
| 中文別名 | N4-羥基胞苷;4-N-羥基胞苷; β-D-N-4-羥基胞苷； β-D-N4-羥基胞苷； N（4）-羥基胞苷； NHC； 尿苷，4-肟; β-D-N4-羥基胞苷 |
| 英文別名 | 4-N-Hydroxycytidine; beta-D-N-4-Hydroxycytidine; Beta-D-N4-hydroxycytidine; N(4)-Hydroxycytidine; NHC; Uridine, 4-oxime; β-D-N4-hydroxycytidine;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)-1,2-dihydropyrimidin-2-one |
| CAS號 | 3258-02-4 |
| Inchi | InChI=1S/C9H13N3O6/c13-3-4-6(14)7(15)8(18-4)12-2-1-5(11-17)10-9(12)16/h1-2,4,6-8,13-15,17H,3H2,(H,10,11,16)/t4-,6-,7-,8-/m1/s1 |
| InchiKey | XCUAIINAJCDIPM-XVFCMESISA-N |
| 分子式 Molecular Weight | C3D11PV2O4 |
| 分子量 Formula | 259.0804352 |
| 溶解度Solubility | Water Solubility,34.4 mg/mL; |
| 性狀 | 固體粉末,Powder |
| 儲藏條件 Storage conditions | Store at -4℃ |
| Stock Solutions of N4-Hydroxycytidine | |||
| Concentration\Solvent\Mass | 1mg | 5mg | 10mg |
| 1 mM | 3.8577 mL | 19.2886 mL | 38.5773 mL |
| 5mM | 0.7715 mL | 3.8577 mL | 7.7155 mL |
| 10mM | 0.3858 mL | 1.9289 mL | 3.8577 mL |
| DMSO：250 mg / mL（964.43 mM；需要超聲）;Water Solubility :34.4 mg/mL | |||
| 產(chǎn)品說明 | A cytidine analog being investigated to treat COVID-19. |
| Introduction | N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.1,2 N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.5 It has shown antiviral activity against Venezuelan equine encephalitis virus,1 and the human coronavirus HCoV-NL63 in vitro.4 N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.3 It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.2 In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.6 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.3 The prodrug of N4-hydroxycytidine, EIDD-2801, is also being investigated for its broad spectrum activity against the coronavirus family of viruses.3 |
| Application1 | 潛在冠狀病毒抑制劑Experimental Unapproved Treatments for COVID-19 |
| Application2 | |
| Application3 |
關(guān)于N4-羥基胞苷過量的數(shù)據(jù)不容易獲得。 N4-羥基胞苷對SARS-CoV-2臨床分離株的治療指數(shù)有望> 100，體外IC50為0.3µM，CC50> 10µM。
Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3µM and a CC50 of >10µM.
Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3µM and a CC50 of >10µM.
| Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I: beta-d-N (4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. J Virol. 2018 Jan 17;92(3). pii: JVI.01965-17. doi: 10.1128/JVI.01965-17. Print 2018 Feb 1. [PubMed:29167335] |
| Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, Guthrie DB, Hager M, Kuiper DL, Lockwood MA, Mitchell DG, Natchus MG, Sticher ZM, Kolykhalov AA: The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019 Nov;171:104597. doi: 10.1016/j.antiviral.2019.104597. Epub 2019 Sep 5. [PubMed:31494195] |
| T. P. Sheahan et al.: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med.. 4.Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, van der Hoek L: Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8. doi: 10.1128/AAC.01598-05. [PubMed:16723558] |
| Sledziewska E, Janion C: Mutagenic specificity of N4-hydroxycytidine. Mutat Res. 1980 Mar;70(1):11-6. doi: 10.1016/0027-5107(80)90053-6. [PubMed:7366595] |
| Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK: Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: 11/515/eaax5866. doi: 10.1126/scitranslmed.aax5866. [PubMed:31645453] |
Hampton T: New Flu Antiviral Candidate May Thwart Drug Resistance. JAMA. 2020 Jan 7;323(1):17. doi: 10.1001/jama.2019.20225.
對不起，暫無產(chǎn)品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實驗
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
胞插件.png)
細(xì)胞培養(yǎng)耗材技術(shù)領(lǐng)先性
細(xì)胞培養(yǎng)板行業(yè)面臨的核心痛點是：常規(guī)TC處理后表面親水角隨時間衰減，影響長期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
胞培養(yǎng)板.jpg)
細(xì)胞培養(yǎng)耗材關(guān)鍵性能
細(xì)胞培養(yǎng)板的水接觸角作為表面潤濕性的核心指標(biāo)，直接影響細(xì)胞貼壁、增殖、分化及功能表達(dá)，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術(shù)與國際市場的雙重突破
在實驗室耗材領(lǐng)域，封口膜是保障實驗準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
